卡介苗作为针对传染病和癌症的新型重组疫苗载体
BCG as a Vector for Novel Recombinant Vaccines against Infectious Diseases and Cancers.
作者信息
Mustafa Abu Salim
机构信息
Department of Microbiology, Faculty of Medicine, Kuwait University, Safat 13110, Kuwait.
出版信息
Vaccines (Basel). 2020 Dec 4;8(4):736. doi: 10.3390/vaccines8040736.
Abstract
Bacillus Calmette-Guérin (BCG) has been widely used globally as a prophylactic vaccine to protect against tuberculosis (TB) for about a century [...].
摘要
卡介苗（BCG）在全球范围内已被广泛用作预防结核病（TB）的疫苗约一个世纪了[...]。
相似文献
1
BCG as a Vector for Novel Recombinant Vaccines against Infectious Diseases and Cancers.卡介苗作为针对传染病和癌症的新型重组疫苗载体
Vaccines (Basel). 2020 Dec 4;8(4):736. doi: 10.3390/vaccines8040736.
2
Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model.在高度易感动物模型中，表达结核分枝杆菌30 kDa主要分泌蛋白的重组卡介苗（BCG）疫苗比传统卡介苗疫苗诱导出更强的抗结核保护性免疫。
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13853-8. doi: 10.1073/pnas.250480397.
3
Past, Present and Future of Bacillus Calmette-Guérin Vaccine Use in China.卡介苗在中国应用的过去、现在与未来
Vaccines (Basel). 2022 Jul 20;10(7):1157. doi: 10.3390/vaccines10071157.
4
Protection against tuberculosis by Bacillus Calmette-Guérin (BCG) vaccination: A historical perspective.卡介苗（BCG）接种预防结核病：历史视角。
Med. 2022 Jan 14;3(1):6-24. doi: 10.1016/j.medj.2021.11.006. Epub 2021 Dec 31.
5
Next-Generation Vaccines Based on Bacille Calmette-Guérin.基于卡介苗的新一代疫苗。
Front Immunol. 2018 Feb 5;9:121. doi: 10.3389/fimmu.2018.00121. eCollection 2018.
6
Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis.用于卡介苗初免的结核异源加强疫苗。
Expert Rev Vaccines. 2007 Aug;6(4):539-46. doi: 10.1586/14760584.6.4.539.
7
Prime-boost bacillus Calmette-Guérin vaccination with lentivirus-vectored and DNA-based vaccines expressing antigens Ag85B and Rv3425 improves protective efficacy against Mycobacterium tuberculosis in mice.用表达抗原Ag85B和Rv3425的慢病毒载体疫苗和DNA疫苗进行初免-加强卡介苗接种可提高小鼠对结核分枝杆菌的保护效力。
Immunology. 2014 Oct;143(2):277-86. doi: 10.1111/imm.12308.
8
Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control.卡介苗作为全球传染病控制的疫苗载体
Tuberc Res Treat. 2011;2011:574591. doi: 10.1155/2011/574591. Epub 2011 May 24.
9
The impact of human single nucleotide polymorphisms on Bacillus Calmette-Guérin responses.人类单核苷酸多态性对卡介苗反应的影响。
Vaccine. 2020 Sep 11;38(40):6224-6235. doi: 10.1016/j.vaccine.2020.07.032. Epub 2020 Aug 18.
10
Vaccines against Tuberculosis: Where Are We Now?抗结核疫苗：我们目前的进展如何？
Vaccines (Basel). 2023 May 22;11(5):1013. doi: 10.3390/vaccines11051013.
引用本文的文献
1
Exploring BCG to deliver avidin fusion antigens from Schistosoma mansoni.探索卡介苗递送曼氏血吸虫抗生物素蛋白融合抗原。
Mem Inst Oswaldo Cruz. 2025 Mar 3;120:e240167. doi: 10.1590/0074-02760240167. eCollection 2025.
2
BCG as immunostimulating agent prevents the severe form of chronic experimental Chagas disease.卡介苗作为免疫刺激剂可预防慢性实验性恰加斯病的严重形式。
Front Immunol. 2024 Mar 21;15:1380049. doi: 10.3389/fimmu.2024.1380049. eCollection 2024.
3
Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response.基于全肿瘤细胞的疫苗：调整仪器以协调最佳抗肿瘤免疫反应。
Br J Cancer. 2023 Sep;129(4):572-585. doi: 10.1038/s41416-023-02327-6. Epub 2023 Jun 24.
4
Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics.利用癌症疫苗激发免疫系统：从预防到治疗
Vaccines (Basel). 2022 May 21;10(5):816. doi: 10.3390/vaccines10050816.
5
Strategies to Develop a Mucosa-Targeting Vaccine against Emerging Infectious Diseases.针对新发传染病开发黏膜靶向疫苗的策略。
Viruses. 2022 Mar 3;14(3):520. doi: 10.3390/v14030520.
6
BCG immunotherapy inhibits cancer progression by promoting the M1 macrophage differentiation of THP‑1 cells via the Rb/E2F1 pathway in cervical carcinoma.BCG 免疫疗法通过 Rb/E2F1 通路促进 THP-1 细胞向 M1 巨噬细胞分化，从而抑制宫颈癌的进展。
Oncol Rep. 2021 Nov;46(5). doi: 10.3892/or.2021.8196. Epub 2021 Sep 28.
7
Adjuvants and Antigen-Delivery Systems for Subunit Vaccines against Tuberculosis.用于结核病亚单位疫苗的佐剂和抗原递送系统
Vaccines (Basel). 2021 Aug 30;9(9):972. doi: 10.3390/vaccines9090972.
8
Recombinant Expressing SARS-CoV-2 Receptor-Binding Domain as a Vaccine Candidate Against SARS-CoV-2 Infections.表达严重急性呼吸综合征冠状病毒2受体结合域的重组体作为抗严重急性呼吸综合征冠状病毒2感染的候选疫苗。
Front Immunol. 2021 Aug 27;12:712274. doi: 10.3389/fimmu.2021.712274. eCollection 2021.
9
Complete Genome Sequence, Genome Stability and Phylogeny of the Vaccine Strain BCG SL222 Sofia.疫苗株卡介苗SL222索菲亚的全基因组序列、基因组稳定性和系统发育
Vaccines (Basel). 2021 Mar 9;9(3):237. doi: 10.3390/vaccines9030237.
10
Immunological Characterization of Proteins Expressed by Genes Located in -Specific Genomic Regions Encoding the ESAT6-like Proteins.位于编码ESAT6样蛋白的特定基因组区域的基因所表达蛋白质的免疫学特征分析
Vaccines (Basel). 2021 Jan 7;9(1):27. doi: 10.3390/vaccines9010027.
本文引用的文献
1
Association between live childhood vaccines and COVID-19 outcomes: a national-level analysis.儿童期疫苗接种与 COVID-19 结局的关联：国家级分析。
Epidemiol Infect. 2021 Mar 16;149:e75. doi: 10.1017/S0950268821000571.
2
Can BCG vaccine protect against COVID-19 via trained immunity and tolerogenesis?BCG 疫苗能否通过训练免疫和耐受原生成来预防 COVID-19？
Bioessays. 2021 Mar;43(3):e2000200. doi: 10.1002/bies.202000200. Epub 2020 Nov 9.
3
Is BCG associated with reduced incidence of COVID-19? A meta-regression of global data from 160 countries.卡介苗与降低新冠病毒疾病（COVID-19）发病率有关联吗？一项对来自160个国家的全球数据的元回归分析。
Clin Epidemiol Glob Health. 2021 Jan-Mar;9:202-203. doi: 10.1016/j.cegh.2020.08.015. Epub 2020 Sep 5.
4
The influence of vaccination against tuberculosis with the Bacillus-Calmette-Guérin(BCG) vaccine on COVID-19 incidence and mortality - review of the literature.卡介苗（BCG）接种对COVID-19发病率和死亡率的影响——文献综述
Przegl Epidemiol. 2020;74(2):290-302. doi: 10.32394/pe.74.22.
5
Protection against SARS-CoV-2 by BCG vaccination is not supported by epidemiological analyses.BCG 疫苗接种不能预防 SARS-CoV-2，这一结论得到了流行病学分析的支持。
Sci Rep. 2020 Oct 27;10(1):18377. doi: 10.1038/s41598-020-75491-x.
6
An Overview of the Development of New Vaccines for Tuberculosis.结核病新型疫苗研发概述
Vaccines (Basel). 2020 Oct 5;8(4):586. doi: 10.3390/vaccines8040586.
7
New disease old vaccine: Is recombinant BCG vaccine an answer for COVID-19?新型疾病旧疫苗：重组卡介苗疫苗能否应对 COVID-19 ？
Cell Immunol. 2020 Oct;356:104187. doi: 10.1016/j.cellimm.2020.104187. Epub 2020 Jul 28.
8
Recombinant Mycobacterium bovis BCG is a promising platform to develop vaccines against Trypansoma cruzi infection.重组牛分枝杆菌是一种有前途的平台，可用于开发针对克氏锥虫感染的疫苗。
Clin Exp Immunol. 2020 Sep;201(3):306-316. doi: 10.1111/cei.13469. Epub 2020 Jul 6.
9
Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy.SAKK 06/14 期开放标签临床试验结果，评估 VPM1002BC（一种重组卡介苗）膀胱内灌注治疗非肌肉浸润性膀胱癌和常规卡介苗治疗失败患者的安全性。
Oncoimmunology. 2020 Apr 21;9(1):1748981. doi: 10.1080/2162402X.2020.1748981. eCollection 2020.
10
BCG: a vaccine with multiple faces.BCG：一种具有多种面貌的疫苗。
Hum Vaccin Immunother. 2020 Aug 2;16(8):1841-1850. doi: 10.1080/21645515.2019.1706930. Epub 2020 Jan 29.
Zotero 插件